Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Suzuken to Exclusively Distribute Novartis’ Zolgensma in Japan
May 21, 2020
- JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
May 20, 2020
- Astellas Confident of Hitting 3-Year Biz Goals on Xtandi, Full Backing of New Products
May 20, 2020
- Stella Pharma Launches New Cancer Radiation Therapy Steboronine
May 20, 2020
- Sawai, Nichi-Iko Hint at Delay in Edirol Generic Debut
May 20, 2020
- Astellas Eases Work-from-Home Policy in 39 Prefectures after Partial COVID-19 Emergency Lift
May 20, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- Mitsubishi Tanabe, Fuso to Copromote HIF-PH Inhibitor
May 19, 2020
- Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Enhertu Gets FDA’s Breakthrough Therapy Status for NSCLC
May 19, 2020
- Japan Ethical Drug Sales Down 2.9% in March: Crecon
May 18, 2020
- 7 Japan Major Drug Makers See Limited Impact from COVID-19: FY2019 Earnings
May 18, 2020
- Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
- Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
- Takeda’s Adcetris Gets EU OK for 1st-Line sALCL Treatment in Combo with Chemo
May 18, 2020
- Chugai Licenses Antibody Engineering Technologies to Lilly in COVID-19 Pact
May 18, 2020
- JT Files Riona for Iron Deficiency Anemia in Japan
May 18, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Ono Files Opdivo for 1st-Line Treatment for Unresectable Advanced/Recurrent Gastric Cancer
May 15, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…